Switch theme
Sign up to access all valuation multiples
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
2007
23
LTM Revenue $1.0M
LTM EBITDA -$4.0M
$3.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Addex Therapeutics has a last 12-month revenue of $1.0M and a last 12-month EBITDA of -$4.0M.
In the most recent fiscal year, Addex Therapeutics achieved revenue of $1.8M and an EBITDA of -$11.6M.
Addex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Addex Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8M | $1.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$11.6M | -$4.1M | XXX | XXX | XXX |
| EBITDA Margin | -634% | -380% | XXX | XXX | XXX |
| Net Profit | -$17.4M | -$23.5M | XXX | XXX | XXX |
| Net Margin | -952% | -2180% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Addex Therapeutics's stock price is CHF 0 (or $0).
Addex Therapeutics has current market cap of CHF 6.7M (or $7.6M), and EV of CHF 3.4M (or $3.9M).
See Addex Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9M | $7.6M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Addex Therapeutics has market cap of $7.6M and EV of $3.9M.
Addex Therapeutics's trades at 3.8x LTM EV/Revenue multiple, and -1.0x LTM EBITDA.
Analysts estimate Addex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Addex Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.9M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | XXX | XXX |
| P/E | 7.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAddex Therapeutics's NTM/LTM revenue growth is -16%
Addex Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Addex Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Addex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Addex Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -41% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -380% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -65% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -396% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 447% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 170% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 737% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Addex Therapeutics acquired XXX companies to date.
Last acquisition by Addex Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Addex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Addex Therapeutics founded? | Addex Therapeutics was founded in 2007. |
| Where is Addex Therapeutics headquartered? | Addex Therapeutics is headquartered in Switzerland. |
| How many employees does Addex Therapeutics have? | As of today, Addex Therapeutics has 23 employees. |
| Who is the CEO of Addex Therapeutics? | Addex Therapeutics's CEO is Mr. Tim Dyer. |
| Is Addex Therapeutics publicy listed? | Yes, Addex Therapeutics is a public company listed on SWX. |
| What is the stock symbol of Addex Therapeutics? | Addex Therapeutics trades under ADXN ticker. |
| When did Addex Therapeutics go public? | Addex Therapeutics went public in 2007. |
| Who are competitors of Addex Therapeutics? | Similar companies to Addex Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Addex Therapeutics? | Addex Therapeutics's current market cap is $7.6M |
| What is the current revenue of Addex Therapeutics? | Addex Therapeutics's last 12-month revenue is $1.0M. |
| What is the current EBITDA of Addex Therapeutics? | Addex Therapeutics's last 12-month EBITDA is -$4.0M. |
| What is the current EV/Revenue multiple of Addex Therapeutics? | Current revenue multiple of Addex Therapeutics is 3.8x. |
| What is the current EV/EBITDA multiple of Addex Therapeutics? | Current EBITDA multiple of Addex Therapeutics is -1.0x. |
| What is the current revenue growth of Addex Therapeutics? | Addex Therapeutics revenue growth between 2023 and 2024 was -41%. |
| Is Addex Therapeutics profitable? | Yes, Addex Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
